Hypoparathyroidism is a rare endocrine disorder characterized by insufficient parathyroid hormone production, which leads to low calcium levels and various symptoms such as muscle cramps and fatigue. The disease affects approximately 23 to 37 cases per 100,000 individuals annually. Current treatment options, including calcium and vitamin D supplements, do not address the underlying cause of the condition, creating a significant unmet clinical need. The growing focus on targeted therapies and novel drug candidates is expected to accelerate the development of hypoparathyroidism therapeutics. In the coming years, advancements in gene therapy and hormone replacement products are likely to enhance pipeline growth and improve patient outcomes.
Major companies involved in the hypoparathyroidism pipeline drugs market include MBX Biosciences, Amorphical Ltd., and others.
Leading drugs currently in the pipeline include TransCon PTH, MBX 2109, AMOR-1, and others.
Advancements in targeted therapies, innovative drug candidates, and a focus on addressing the disease's underlying causes are likely to positively impact the hypoparathyroidism pipeline landscape.
The Hypoparathyroidism Drug Pipeline Insight Report by Expert Market Research gives comprehensive insights into hypoparathyroidism therapeutics currently undergoing clinical trials. It covers various aspects related to the details of each of these drugs under development for hypoparathyroidism. The hypoparathyroidism report assessment includes the analysis of over 100 pipeline drugs and 50+ companies. The hypoparathyroidism pipeline landscape will include an analysis based on efficacy and safety measure outcomes published for the trials, including their adverse effects on patients suffering from the condition, and alignment with hypoparathyroidism treatment guidelines to ensure optimal care practices.
The assessment part will include a detailed analysis of each drug, drug class, clinical studies, phase type, drug type, route of administration, and ongoing product development activities related to hypoparathyroidism.
Read more about this report - REQUEST FREE SAMPLE COPY IN PDF
Hypoparathyroidism is a rare endocrine disorder where the parathyroid glands produce insufficient parathyroid hormone (PTH), leading to low calcium and high phosphate levels. This condition can occur due to damage or removal of the parathyroid glands, autoimmune diseases, or genetic mutations. The low calcium levels result in symptoms like muscle spasms, seizures, and fatigue.
Hypoparathyroidism treatment typically involves calcium and vitamin D supplementation to maintain calcium levels. However, these do not address the root cause. Newer therapies include recombinant PTH (1-34) injections, which help restore calcium balance, offering a more effective treatment option for long-term management.
The estimated prevalence of hypoparathyroidism is approximately 23 to 37 cases per 100,000 individuals annually. In the United States, the prevalence ranges from 6.4 to 37 per 100,000, with 75% of cases resulting from complications of thyroidectomy or head and neck surgeries. In the United Kingdom, chronic hypoparathyroidism is considered rare, with a prevalence of 37 per 100,000 individuals.
This section of the report covers the analysis of hypoparathyroidism drug candidates based on several segmentations, including:
By Phase
By Drug Class
By Route of Administration
The report covers phase I, phase II, phase III, phase IV, and early-phase drugs. The coverage includes an in-depth analysis of each drug across these phases. According to EMR analysis, phase II covers a major share of the total hypoparathyroidism clinical trials.
The drug molecule categories covered under the hypoparathyroidism pipeline analysis include small molecules, peptides, monoclonal antibodies, and gene therapies. The hypoparathyroidism report provides a comparative analysis of the drug classes for each drug in various phases of clinical trials for hypoparathyroidism.
The EMR report for the hypoparathyroidism drug pipeline covers the profile of key companies involved in clinical trials and their drugs under development. It provides a detailed hypoparathyroidism therapeutic assessment, analyzing the competitive dynamics of the clinical trial landscape. Below is the list of a few players involved in hypoparathyroidism clinical trials:
This section covers the detailed analysis of each drug under multiple phases, including phase I, phase II, phase III, phase IV, and emerging drugs for hypoparathyroidism. It includes product description, trial ID, study type, drug class, mode of administration, and recruitment status of hypoparathyroidism drug candidates.
The PaTHway China Trial, sponsored by Visen Pharmaceuticals, is a Phase III study investigating the safety, tolerability, and efficacy of TransCon PTH in adults with hypoparathyroidism. The primary objective is to assess the treatment effect on serum calcium levels and reduce dependence on active vitamin D and calcium supplements. The study will enroll approximately 76 participants and is expected to be completed by December 2025.
The Phase II study, sponsored by MBX Biosciences, aims to evaluate the safety, pharmacokinetics, and efficacy of MBX 2109 in patients with hypoparathyroidism. The objective is to assess if MBX 2109 can maintain normal serum calcium levels without the need for active vitamin D and calcium supplements. The study is expected to be completed by July 2025, with around 48 participants.
The Phase II clinical trial, sponsored by Amorphical Ltd., seeks to evaluate the safety and efficacy of AMOR-1 as a treatment for hypocalcemia in adults with hypoparathyroidism. The study will assess whether AMOR-1, containing amorphous calcium carbonate, can replace current calcium supplements. The trial is expected to be completed by September 2026, with an estimated 81 participants enrolled.
*Please note that this is only a partial list; the complete list of drugs will be available in the full report.*
The Hypoparathyroidism Drug Pipeline Insight Report provides a strategic overview of the latest and future landscape of treatments for hypoparathyroidism. It provides necessary information for making informed investment decisions along with research, development, and strategic planning efforts. The stakeholders will benefit from the essential insights into hypoparathyroidism collaborations, regulatory environments, and potential growth opportunities.
Thyroid Gland Disorder Treatment Market
Global Anaplastic Thyroid Cancer Drugs Market
Upto 15% Off
USD
$1999 $1799
$3099 $2789
$4599 $3909
$5999 $5099
*While we strive to always give you current and accurate information, the numbers depicted on the website are indicative and may differ from the actual numbers in the main report. At Expert Market Research, we aim to bring you the latest insights and trends in the market. Using our analyses and forecasts, stakeholders can understand the market dynamics, navigate challenges, and capitalize on opportunities to make data-driven strategic decisions.*
Get in touch with us for a customized solution tailored to your unique requirements and save upto 35%!
Explore our key highlights of the report and gain a concise overview of key findings, trends, and actionable insights that will empower your strategic decisions.
|
Scope of the Report |
Details |
|
Drug Pipeline by Clinical Trial Phase |
|
|
Route of Administration |
|
|
Drug Classes |
|
|
Leading Sponsors Covered |
|
|
Geographies Covered |
|
Mini Report
One User
USD 1,999
USD 1,799
tax inclusive*
Single User License
One User
USD 3,099
USD 2,789
tax inclusive*
Five User License
Five User
USD 4,599
USD 3,909
tax inclusive*
Corporate License
Unlimited Users
USD 5,999
USD 5,099
tax inclusive*
*Please note that the prices mentioned below are starting prices for each bundle type. Kindly contact our team for further details.*
Flash Bundle
Small Business Bundle
Growth Bundle
Enterprise Bundle
*Please note that the prices mentioned below are starting prices for each bundle type. Kindly contact our team for further details.*
Flash Bundle
Number of Reports: 3
20%
tax inclusive*
Small Business Bundle
Number of Reports: 5
25%
tax inclusive*
Growth Bundle
Number of Reports: 8
30%
tax inclusive*
Enterprise Bundle
Number of Reports: 10
35%
tax inclusive*
How To Order
Select License Type
Choose the right license for your needs and access rights.
Click on ‘Buy Now’
Add the report to your cart with one click and proceed to register.
Select Mode of Payment
Choose a payment option for a secure checkout. You will be redirected accordingly.
Gain insights to stay ahead and seize opportunities.
Get insights & trends for a competitive edge.
Track prices with detailed trend reports.
Analyse trade data for supply chain insights.
Leverage cost reports for smart savings
Enhance supply chain with partnerships.
Connect For More Information
Our expert team of analysts will offer full support and resolve any queries regarding the report, before and after the purchase.
Our expert team of analysts will offer full support and resolve any queries regarding the report, before and after the purchase.
We employ meticulous research methods, blending advanced analytics and expert insights to deliver accurate, actionable industry intelligence, staying ahead of competitors.
Our skilled analysts offer unparalleled competitive advantage with detailed insights on current and emerging markets, ensuring your strategic edge.
We offer an in-depth yet simplified presentation of industry insights and analysis to meet your specific requirements effectively.
Share